Effect of curcumin combined with vedolizumab on disease activity in patients with moderate to severe ulcerative colitis and its correlation with inflammatory and immune factors.

Front Med (Lausanne) · 2026 · PMC13082993 · PMID 42006893

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

did not reach statistical significanceP > 0.05actually significant

Although the combination therapy group had a slightly lower RHI score than the VDZ group, the difference between the two groups did not reach statistical significance ( P > 0.05; Table 6 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.